Please assess the completion status of the following clinical trial:

Trial Title: Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* Documented history of perennial allergic rhinitis~* A demonstrated sensitivity to at least one allergen known to induce PAR through a standard skin prick test.~* Minimum subject-reported reflective total nasal symptom score (rTNSS) of at least 6 (out of a possible 12)~* Other criteria apply~Exclusion Criteria:~* History of physical findings of nasal pathology (within 60 days prior to screening visit)~* Participation in any investigational drug study 30 days preceding screening visit~* History of respiratory infection/disorder with 14 days preceding screening visit or during the run-in period~* Use of any prohibited concomitant medications

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BDP HFA 320 µg/day (Type: EXPERIMENTAL): During the 6-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
- Placebo (Type: PLACEBO_COMPARATOR): During the 6-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).